Research programme: quinolone antibacterials - Procter & Gamble
Alternative Names: (3S)-Amino-(4R)-ethylpiperidinyl quinolones research programme - Procter & Gamble; 5,6-Bridged dioxinoquinolones research programme - Procter & Gamble; Non-fluorinated quinolones research programme - Procter & Gamble; PGE 836779; Quinolone antibacterials research programme - Procter & GambleLatest Information Update: 01 Dec 2009
At a glance
- Originator Procter & Gamble
- Class Quinolones
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 06 Jan 2005 TaiGen Biotechnology entered a strategic alliance with Procter & Gamble for further development and commercialisation of an unspecified, non-fluorinated quinolone invented by Procter & Gamble. TaiGen has development and commercialisation rights in China, Taiwan, Korea and the ASEAN countries
- 07 Jan 2004 A preclinical study has been added to the Bacterial Infections antimicrobial activity section
- 05 Sep 2003 This programme is still in active development